1. Establishing a Trial Ready Cohort to Accelerate Alzheimer’s Clinical Trial Enrollment and Treatments

   • E. A. Meyers
   • Maria C. Carrillo

   Editorial 11 August 2020 Pages: 202 - 203

2. Accelerating Preclinical Alzheimer’s Clinical Trials through a Trial-Ready Cohort with Diverse Representation

   • A. K. W. Lee
   • S. Correia
   • Stephen P. Salloway

   Editorial 11 August 2020 Pages: 204 - 205

3. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) — A Fundamental Ally in AD Prevention Research

   • A. P. Porsteinsson
   • E. D. Clark

   Editorial 11 August 2020 Pages: 206 - 207

4. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview

   • P. S. Aisen
   • R. A. Sperling
   • R. Raman

   Special Article Open access 11 August 2020 Pages: 208 - 212

   

5. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials

   • O. Langford
   • R. Raman
   • TRC-PAD Investigators

   Special Article Open access 11 August 2020 Pages: 213 - 218

   

6. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)

   • S. Walter
   • T. B. Clanton
   • TRC-PAD Investigators

   Special Article Open access 11 August 2020 Pages: 219 - 225

   

7. TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology

   • G. A. Jimenez-Maggiora
   • S. Bruschi
   • TRC-PAD Investigators

   Special Article Open access 16 August 2020 Pages: 226 - 233

   

8. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years

   • S. Walter
   • O. G. Langford
   • TRC-PAD Investigators

   Special Article Open access 13 August 2020 Pages: 234 - 241

   

9. The Alzheimer’s Prevention Registry: A Large Internet-Based Participant Recruitment Registry to Accelerate Referrals to Alzheimer’s-Focused Studies

   • Jessica B. Langbaum
   • N. High
   • P. N. Tariot

   Original Research Open access 25 May 2020 Pages: 242 - 250

10. Effectiveness of the Open Screening Programs in Recruiting Subjects to Prodromal and Mild Alzheimer’s Disease Clinical Trials

    • Daniel Wójcik
    • K. Szczechowiak
    • M. Pikala

    Original Research 02 March 2020 Pages: 251 - 255

    

11. PTI-125 Reduces Biomarkers of Alzheimer’s Disease in Patients

    • H.-Y. Wang
    • Z. Pei
    • Lindsay H. Burns

    Original Research 07 February 2020 Pages: 256 - 264

    

12. The Interrelationship between Insulin-Like Growth Factor 1, Apolipoprotein E ε4, Lifestyle Factors, and the Aging Body and Brain

    • Sara A. Galle
    • I.K. Geraedts
    • M.L. Drent

    Reviews Open access 02 March 2020 Pages: 265 - 273

13. A Framework for Developing Pharmacotherapy for Agitation in Alzheimer’s disease: Recommendations of the ISCTM Working Group

    • Cedric O’Gorman
    • R. Khoury
    • ISCTM: International Society for CNS Clinical Trials and Methodology

    Reviews Open access 26 June 2020 Pages: 274 - 282

14. Self-Administered Cognitive Testing by Older Adults At-Risk for Cognitive Decline

    • Elena Tsoy
    • K. L. Possin
    • C. S. Ritchie

    Brief Reports 24 April 2020 Pages: 283 - 287

    

15. The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs

    • Jeffrey Cummings

    Viewpoint Open access 06 May 2020 Pages: 288 - 290

16. A Missed Opportunity for Dementia Prevention? Current Challenges for Early Detection and Modern-Day Solutions

    • Richard S. Isaacson
    • N. Saif

    Viewpoint Open access 17 April 2020 Pages: 291 - 293

17. The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline

    • Harald Hampel
    • Andrea Vergallo

    Viewpoint 13 July 2020 Pages: 294 - 298

    

18. Letter to the editor referring to P.S. Aisen and R. Raman, Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business. The Journal of Prevention of Alzheimer’s Disease, 2020

    • Daniel Umbricht

    Letter to the Editor 01 June 2020 Pages: 299 - 300

19. Authors response to D. Umbricht letter to the editor referring Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business. The Journal of Prevention of Alzheimer’s Disease, 2020

    • P. S. Aisen
    • R. Raman

    Response to the Letter to the Editor 01 June 2020 Pages: 300 - 300

20. Toulouse Alzheimer’s Clinical Research Center Recovery after the COVID-19 Crisis: Telemedicine an Innovative Solution for Clinical Research during the Coronavirus Pandemic

    • C. Takeda
    • S. Guyonnet
    • B. Vellas

    Letter to the Editor 25 May 2020 Pages: 301 - 304